CHLORDIAZEPOXIDE HYDROCHLORIDE Drug Interactions
Also known as: Chlordiazepoxide Hydrochloride
Chlordiazepoxide Hydrochloride is a benzodiazepine medication used to treat anxiety disorders and provide short-term relief for symptoms of anxiety. It can also help manage withdrawal symptoms from acute alcoholism and reduce anxiety before surgery. This medication works by calming the brain and nerves.CHLORDIAZEPOXIDE HYDROCHLORIDE has 10 documented drug interactions in our database, including 9 contraindicated, 1 major, 0 moderate, and 0 minor interactions.
9
Contraindicated
1
Major
0
Moderate
0
Minor
The combination significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may exhibit somnolence, decreased respiratory rate, hypoxemia, and unresponsiveness. This can rapidly progress to life-threatening respiratory arrest.
Mechanism
Both buprenorphine (an opioid partial agonist) and chlordiazepoxide (a benzodiazepine) are central nervous system (CNS) depressants. Their co-administration leads to an additive depressant effect on the CNS, particularly affecting the respiratory drive and level of consciousness. This synergistic depression is primarily mediated through their respective actions on opioid receptors and GABA-A receptors.
Clinical Management
Concurrent use of buprenorphine and chlordiazepoxide is generally contraindicated due to the high risk. If co-administration is unavoidable and strictly medically necessary, use the lowest effective doses for the shortest duration possible, and monitor patients closely for signs of respiratory depression and sedation. Consider alternative treatments that do not involve concurrent opioid and benzodiazepine use.
Concomitant use can lead to severe adverse effects including profound sedation, respiratory depression, coma, and death. Patients may exhibit decreased level of consciousness, hypoventilation, hypoxia, and hypotension.
Mechanism
Fentanyl, an opioid agonist, and chlordiazepoxide, a benzodiazepine, both act as central nervous system (CNS) depressants. Their co-administration results in an additive and synergistic depressant effect on the CNS, particularly on brainstem respiratory centers, leading to profound respiratory depression.
Clinical Management
Concomitant use of fentanyl and chlordiazepoxide is generally contraindicated due to the high risk of serious adverse outcomes. If co-administration is absolutely necessary and no alternatives exist, use the lowest effective doses for the shortest duration possible, and monitor patients closely for signs of respiratory depression and sedation. Have naloxone readily available.
This interaction leads to profound sedation, respiratory depression, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, bradycardia, and hypotension. The risk of overdose and fatal outcomes is significantly increased.
Mechanism
Oxycodone, an opioid agonist, and chlordiazepoxide hydrochloride, a benzodiazepine, both exert central nervous system (CNS) depressant effects by different mechanisms. Opioids primarily act on mu-opioid receptors, while benzodiazepines enhance the effect of the inhibitory neurotransmitter GABA at GABA-A receptors. The concomitant use of these agents results in an additive and synergistic CNS depression.
Clinical Management
Concomitant use of oxycodone and chlordiazepoxide hydrochloride should be avoided due to the severe risks, as highlighted by an FDA Black Box Warning. If co-prescription is absolutely necessary and no alternatives are available, the lowest effective doses should be used for the shortest possible duration, with close monitoring for respiratory depression and sedation. Patients and caregivers must be educated on the risks and symptoms, and naloxone should be prescribed for opioid overdose reversal.
Concomitant use significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, bradycardia, and hypotension. This interaction poses a life-threatening risk.
Mechanism
Morphine, an opioid agonist, and chlordiazepoxide, a benzodiazepine, both produce central nervous system (CNS) depression by different mechanisms. Opioids primarily act on mu-opioid receptors, while benzodiazepines enhance the effect of the inhibitory neurotransmitter GABA at the GABA-A receptor. The synergistic CNS depressant effects lead to profound respiratory depression, sedation, and hypotension.
Clinical Management
The co-administration of morphine and chlordiazepoxide is contraindicated due to the high risk of severe adverse outcomes. If concurrent use is unavoidable, which should be rare, patients must be closely monitored for respiratory depression and sedation, and doses should be significantly reduced. Naloxone and flumazenil should be readily available for emergency reversal.
The combination significantly increases the risk of profound sedation, respiratory depression, coma, and death. Patients may experience extreme drowsiness, confusion, dizziness, slowed or difficult breathing, and unresponsiveness.
Mechanism
Both tramadol (an opioid analgesic) and chlordiazepoxide (a benzodiazepine) are central nervous system (CNS) depressants. Their co-administration leads to additive CNS depression, primarily by enhancing gamma-aminobutyric acid (GABA)ergic neurotransmission (benzodiazepine) and acting on opioid receptors (tramadol), resulting in synergistic effects on respiratory and CNS function.
Clinical Management
Concomitant use of tramadol and chlordiazepoxide should be avoided. If alternative treatments are not adequate, and co-prescription is absolutely necessary, the lowest effective doses should be used for the shortest possible duration, and patients must be closely monitored for respiratory depression and sedation. Prescribers should warn patients and caregivers of these risks.
The concurrent use of codeine and chlordiazepoxide can lead to profound sedation, respiratory depression, coma, and death. Patients may experience dizziness, confusion, psychomotor impairment, and hypotension. The risk is heightened in patients with pre-existing respiratory conditions, the elderly, and those receiving higher doses of either medication.
Mechanism
Codeine sulfate is an opioid analgesic that acts on mu-opioid receptors in the central nervous system (CNS), leading to CNS depression, including respiratory depression and sedation. Chlordiazepoxide hydrochloride is a benzodiazepine that enhances the effect of gamma-aminobutyric acid (GABA), the primary inhibitory neurotransmitter in the CNS, resulting in further CNS depression. The additive CNS depressant effects of these two drug classes significantly increase the risk of severe adverse outcomes.
Clinical Management
The co-prescription of codeine and chlordiazepoxide is generally contraindicated due to the severe risks. If co-administration is unavoidable and no safer alternative exists, it should be done with extreme caution, using the lowest effective doses for the shortest possible duration, and with close monitoring for signs of respiratory depression and sedation. Patients and caregivers must be educated on these risks and advised to seek immediate medical attention if symptoms occur. Consider naloxone availability.
The primary clinical effects include profound sedation, respiratory depression, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, hypoxia, and hypotension. These effects can be rapid in onset and life-threatening.
Mechanism
Hydromorphone, an opioid agonist, binds to mu-opioid receptors in the central nervous system (CNS), leading to CNS depression, including respiratory depression and sedation. Chlordiazepoxide, a benzodiazepine, enhances the effect of the inhibitory neurotransmitter GABA at GABA-A receptors, also resulting in CNS depression. The co-administration of these two CNS depressants produces additive and synergistic effects on GABAergic and opioid pathways, significantly increasing the risk of severe CNS and respiratory depression.
Clinical Management
Concomitant use of hydromorphone and chlordiazepoxide is generally contraindicated due to the high risk of severe adverse outcomes, as highlighted by an FDA Black Box Warning. If co-administration is absolutely unavoidable, use the lowest effective doses for the shortest possible duration, and closely monitor patients for signs of respiratory depression and sedation. Consider alternative therapies that do not involve co-prescribing opioids and benzodiazepines.
The concurrent use of oxymorphone and chlordiazepoxide significantly increases the risk of severe respiratory depression, profound sedation, coma, and death. Patients may exhibit decreased level of consciousness, hypoventilation, pinpoint pupils, and hypotension.
Mechanism
Both oxymorphone, an opioid agonist, and chlordiazepoxide, a benzodiazepine, are central nervous system (CNS) depressants. Their co-administration leads to synergistic depression of the CNS, primarily by enhancing GABAergic neurotransmission, which results in profound respiratory depression and sedation.
Clinical Management
Concomitant use of opioids and benzodiazepines is generally contraindicated due to the high risk of severe adverse outcomes. If no alternative treatments are adequate, and the benefits outweigh the risks, prescribe the lowest effective doses for the shortest duration possible, and monitor patients closely for respiratory depression and sedation. Consider naloxone availability and patient education on overdose symptoms.
The concurrent use of tapentadol and chlordiazepoxide significantly increases the risk of profound sedation, respiratory depression, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, hypotension, and psychomotor impairment.
Mechanism
Tapentadol, an opioid analgesic with mu-opioid receptor agonism and norepinephrine reuptake inhibition, and chlordiazepoxide, a benzodiazepine that enhances GABAergic neurotransmission, both produce central nervous system (CNS) depression. Their co-administration results in synergistic depressant effects on the CNS, particularly on brainstem respiratory centers.
Clinical Management
Due to the severe risks, concomitant use of tapentadol and chlordiazepoxide is generally contraindicated. If no suitable alternative treatment options are available, and the benefits outweigh the risks, prescribe the lowest effective doses for the shortest duration possible, and monitor patients closely for signs of respiratory depression and sedation. Advise patients and caregivers about the risks and symptoms of CNS depression.
The concurrent use of methadone and chlordiazepoxide can result in severe and potentially fatal outcomes, including profound sedation, respiratory depression, coma, and death. Patients may experience decreased level of consciousness, hypoventilation, apnea, and hypotension. These effects are particularly dangerous in opioid-tolerant individuals who may still be susceptible to benzodiazepine-induced respiratory depression.
Mechanism
Methadone, an opioid agonist, and chlordiazepoxide, a benzodiazepine, both depress the central nervous system (CNS) by different mechanisms. Methadone acts primarily on mu-opioid receptors, while chlordiazepoxide enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors. Their combined CNS depressant effects are synergistic, leading to profound respiratory depression, sedation, and hypotension.
Clinical Management
Concomitant prescribing of opioids and benzodiazepines should generally be avoided due to the high risk of severe adverse outcomes. If co-prescribing is absolutely necessary, use the lowest effective doses and shortest possible durations, and closely monitor patients for signs of respiratory depression and sedation. Educate patients and caregivers about the risks and symptoms, and consider prescribing naloxone for overdose reversal.
For complete prescribing information:
View full CHLORDIAZEPOXIDE HYDROCHLORIDE monograph →Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.